

Petition for Inter Partes Review of USPN 5,856,336

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Mylan Pharmaceuticals Inc., Petitioner

v.

Nissan Chemical Industries Ltd.
Patent Owner

U.S. Patent No. 5,856,336 to Fujikawa *et al.*
Issue Date: January 5, 1999
Title: Quinoline Type Mevalonolactones

Inter Partes Review No.: IPR2015-01069

**Petition for *Inter Partes* Review of U.S. Patent No. 5,856,336
Under 35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	MANDATORY NOTICES (37 C.F.R. § 42.8(A)(1)).....	1
A.	Each Real Party-in-Interest (37 C.F.R. § 42.8(b)(1))	1
B.	Notice of Related Matters (37 C.F.R. § 42.8(b)(2))	1
1.	Judicial Matters Involving the '336 patent	1
2.	Administrative Matters	2
C.	Designation of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))	2
D.	Notice of Service Information (37 C.F.R. § 42.8(b)(4))	2
III.	GROUNDINGS FOR STANDING (37 C.F.R. § 42.104(A)) AND PROCEDURAL STATEMENTS.....	2
IV.	IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(B)) AND STATEMENT OF THE PRECISE RELIEF REQUESTED (37 C.F.R. § 42.22(A)).....	3
V.	THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW	5
VI.	STATEMENT OF REASONS FOR THE RELIEF REQUESTED (37 C.F.R. § 42.22(A)).....	5
A.	Summary of the Argument.....	5
B.	The Claims of the '336 Patent.....	6
C.	The Priority Date of the '336 Patent.....	10
1.	The Earliest Effective Date for the Challenged Claims of the '336 Patent Is August 3, 1988	10
VII.	THE '336 PATENT AND CLAIM CONSTRUCTION	15
A.	POSA.....	15
B.	Ground 1: Claims 1 and 2 of the '336 Patent Are Unpatentable Under 35 U.S.C. § 103	16
1.	The Scope and Content of the Prior Art	16
2.	Legal Principles Regarding Structural Obviousness.....	16
3.	Claim 1 Would Have Been Obvious under 35 U.S.C. § 103.....	17
4.	Claim 2 Would Have Been Obvious Under 35 U.S.C. § 103.....	47

Petition for Inter Partes Review of USPN 5,856,336

5.	Fluvastatin Would Have Been Selected as the Lead Compound for at Least the Following Additional Reasons	50
6.	Any Secondary Considerations Fail to Overcome the Showing of Obviousness	57
C.	Ground 2: Claims 1 and 2 of the '336 Patent are Unpatentable Under 35 U.S.C. § 102 in View of the Picard '419 Patent.....	58
VIII.	CONCLUSION.....	60

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Abbie Inc. v. Mathilda & Terence Kennedy Inst. of Rheumatology Trust</i> , 764 F.3d 1366 (Fed. Cir. 2014).....	59
<i>Aventis Pharma Deutschland GmbH v. Lupin, Ltd.</i> , 499 F.3d 1293 (Fed. Cir. 2007).....	42, 43
<i>Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc.</i> , 752 F.3d 967 (Fed. Cir. 2014).....	passim
<i>Daiichi Sankyo Co. v. Matrix Labs., Ltd.</i> , 619 F.3d 1346 (Fed. Cir. 2010).....	36
<i>Eisai Co. v. Dr. Reddy's Labs., Ltd.</i> , 533 F.3d 1353 (Fed. Cir. 2008).....	54
<i>Eli Lilly and Co. v. Zenith Goldline Pharma, Inc.</i> , 471 F.3d 1369 (2006)	17
<i>In re Aller</i> , 220 F.2d 454 (C.C.P.A. 1955)	49
<i>In re Dillon</i> , 919 F.2d 688 (Fed. Cir. 1990).....	39
<i>In re Gosteli</i> , 872 F.2d 1008 (Fed. Cir. 1989).....	13
<i>In re Ruschig</i> , 379 F.2d 990 (C.C.P.A. 1967)	13
<i>In re Wilder</i> , 563 F.2d 457 (C.C.P.A. 1977)	39
<i>KSR Int'l Co. v. Teleflex, Inc.</i> , 550 U.S. 398 (2007).....	5, 15
<i>Newell Cos., Inc. v. Kenney Mfg. Co.</i> , 864 F.2d 757 (Fed. Cir. 1988).....	57

Otsuka Pharm. Co., Ltd. v. Sandoz, Inc.,
678 F.3d 1280 (Fed. Cir. 2012).....17, 28, 45

Pfizer, Inc. v. Apotex, Inc.,
480 F.3d 1348 (Fed. Cir. 2008).....passim

PowerOasis, Inc. v. T-Mobile USA, Inc.,
522 F.3d 1299 (Fed. Cir. 2008) 13

Schering Corp. v. Geneva Pharm., Inc.,
339 F.3d 1373 (Fed. Cir. 2003).....58, 59

SkinMedica, Inc. v. Histogen, Inc.,
727 F.3d 1187 (Fed. Cir. 2013)..... 48

Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd.,
492 F.3d 1350 (Fed. Cir. 2007)..... 17

OTHER CASES

Amneal Pharm., LLC v. Supernus Pharm., Inc.
IPR2013-00368 57

Kowa Company, Ltd. et al v. Amneal Pharmaceuticals, LLC,
1:14-cv-02758 (S.D.N.Y., Apr. 17, 2014)..... 1

Kowa Company, Ltd. et al v. Aurobindo Pharma Limited et al.,
1:14-cv-02497 (S.D.N.Y., Apr. 9, 2014)..... 2

Kowa Company, Ltd. et al v. Mylan, Inc. et al.,
1:14-cv-02647 (S.D.N.Y., Apr. 14, 2014)..... 1

Kowa Company, Ltd. et al v. Orient Pharma Co., Ltd.,
1:14-cv-02759 (S.D.N.Y., Apr. 17, 2014)..... 1

Kowa Company, Ltd. et al v. Sawai USA, Inc. et al.,
1:14-cv-05575 (S.D.N.Y., July 23, 2014) 1

Kowa Company, Ltd. et al v. Zydus Pharmaceuticals (USA) Inc. et al.,
1:14-cv-02760 (S.D.N.Y., Apr. 17, 2014)..... 1

Metrics, Inc. v. Senju Pharm. Co.,
IPR 2014-01041 49

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.